Imugene Limited (AU:IMU) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Imugene Limited has secured a significant capital boost of up to A$46 million through the issuance of convertible notes and warrants to CVI Investments Inc. This funding is set to support the company’s clinical trials, including programs like azer-cel, onCARlytics, and VAXINIA, extending its cash runway to the end of 2025. The move positions Imugene to anticipate pivotal clinical data in the coming year, offering potential growth opportunities for investors.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
